Abstract
The 27th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held on October 26–28, 2012 in North Bethesda, Maryland and the highlights of the meeting are summarized. The topics covered at this meeting included advances in cancer treatment using adoptive cell therapy (ACT), oncolytic viruses, dendritic cells (DCs), immune check point modulators and combination therapies. Advances in immune editing of cancer, immune modulation by cancer and the tumor microenvironment were also discussed as were advances in single cell analysis and the manufacture and potency testing of tumor infiltrating lymphocytes (TIL).
Highlights
The 27th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held on October 26–28, 2012 in North Bethesda, Maryland and the highlights of the meeting are summarized
The reduction in the number of T cells and proliferation of TREG cells is mediated in part by tumor-derived exosomes (TEX) whose levels are increased in the sera of cancer patients [2]
Cassian Yee (MD Anderson Cancer Center, Houston, TX, USA) reported that conditioning patients with high dose cyclophosphamide alone followed by the infusion of peripheral blood mononuclear cell-derived, antigen specific CD8+ CTL clones in melanoma patients has resulted in the long-term persistence of T cells and, that differentiated effector T cells could revert to a central memory phenotype in vivo following adoptive transfer [12]
Summary
The 27th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held on October 26–28, 2012 in North Bethesda, Maryland and the highlights of the meeting are summarized. Cassian Yee (MD Anderson Cancer Center, Houston, TX, USA) reported that conditioning patients with high dose cyclophosphamide alone followed by the infusion of peripheral blood mononuclear cell-derived, antigen specific CD8+ CTL clones in melanoma patients has resulted in the long-term persistence of T cells and, that differentiated effector T cells could revert to a central memory phenotype in vivo following adoptive transfer [12]. Michel Sadelain and colleagues (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) are attempting to improve the safety of CAR T cell therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.